Press Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds Oct 20 • 6 min read Revive Therapeutics Ltd. announced it has signed an agreement with Havn Life Sciences Inc. to source naturally-derived psychedelic compounds for use in future investigational new drug.
Press Havn Life Sciences submits range of natural health products to Health Canada Sep 24 • 2 min read Havn Life Sciences Inc. announced that it has submitted formulations for its natural health products to Health Canada.
Press Havn Life Sciences granted Section 56 exemption to begin scientific work with psilocybin Sep 11 • 3 min read Havn Life Sciences Inc. announced that its subsidiary HAVN Research Inc. was granted Section 56 exemption, allowing the company to possess certain amounts of psilocybin.
Press Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE Sep 8 • 6 min read Havn Life Sciences Inc. announced that it has commenced trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol “HAVN”.
Press Havn Life Sciences Announces Filing of Final Prospectus and Conditional Approval for Listing on CSE Sep 3 • 2 min read If final CSE approval is received, the Common Shares will commence trading under the symbol “HAVN.”